Claims for Patent: 9,677,087

Summary for Patent: 9,677,087

Title:	Vectors and methods for long-term immune evasion to prolong tranplant viability
Abstract:	A method can include making one or more compositions for altering allogeneic cells of a human donor for a human recipient by identifying at least one mismatch in an HLA protein between the human donor and the human recipient; determining a consensus conserved nucleic acid sequence among nucleic acid sequences encoding a domain having the mismatch or among domains having a plurality of mismatches; and forming at least one of the one or more compositions by constructing a virus vector for expressing a sequence targeting the consensus conserved nucleic acid sequence, which when expressed in cells functions as a negative modulator for nucleic acid encoding the domain having the mismatch or the domains having the plurality of mismatches.
Inventor(s):	Cicciarelli; James C. (Rolling Hills, CA), Kasahara; Noriyuki (Los Angeles, CA), Logg; Christopher R. (South Pasedena, CA)
Assignee:	NATIONAL INSTITUTE OF TRANSPLANTATION FOUNDATION (Los Angeles, CA)
Application Number:	13/567,064
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,677,087
Patent Claims:	1. A method of making a kit that comprises a set of lentivirus vectors for altering allogeneic human cells for a human recipient, the method comprising: forming the set of lentivirus vectors wherein each of the lentivirus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a negative modulator for nucleic acid encoding a domain having a mismatch in an HLA protein and wherein the set of lentivirus vectors comprises individual lentivirus vectors that correspond to individual HLA mismatches for a set of HLA mismatches that consist of HLA Class I mismatches and at least one HLA Class II mismatch; wherein the kit is for treatment of human cells by an appropriate subset of the set of lentivirus vectors based on determining a subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient. 2. The method of claim 1 wherein the sequence comprises an siRNA sequence. 3. The method of claim 1 wherein the at least one of the lentivirus vectors comprises a marker gene cassette for expressing a fluorescent protein for detection of cells transduced by the at least one of the lentivirus vectors. 4. The method of claim 3 comprising forming another one of the lentivirus vectors by constructing it without the marker gene cassette. 5. The method of claim 1 comprising forming an additional composition by contacting the at least one of the lentivirus vectors with cells wherein the additional composition comprises at least some of the contacted cells or a population of cells derived from at least some of the contacted cells. 6. The method of claim 5 wherein the additional composition comprises one or more additional therapeutic agents. 7. The method of claim 6 wherein the one or more additional therapeutic agents comprises a member selected from a group consisting of growth factors, anti-inflammatory agents, vasopressor agents, collagenase inhibitors, topical steroids, matrix metalloproteinase inhibitors, ascorbates, angiotensin II, angiotensin III, calreticulin, tetracyclines, fibronectin, collagen, thrombospondin, transforming growth factors (TGF), keratinocyte growth factor (KGF), fibroblast growth factor (FGF), insulin-like growth factors (IGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), neu differentiation factor (NDF), hepatocyte growth factor (HGF), B vitamins, and hyaluronic acid. 8. The method of claim 1 comprising forming lentivirus vector compositions wherein the lentivirus vector compositions each comprise a different level of its respective lentivirus vector. 9. The method of claim 1 wherein forming the lentivirus vectors comprises forming the lentivirus vectors as compositions in a dosage unit form. 10. The method of claim 9 comprising estimating the dosage unit form using an animal model. 11. The method of claim 1 comprising formulating a range of dosages for the lentivirus vectors based at least in part on data obtained from an animal study. 12. A subset of the set of lentivirus vectors of the kit of claim 1 formed based on determination of a subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient. 13. The method of claim 1 further comprising forming a subset of the set of lentivirus vectors from the kit based on determining a subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient. 14. The method of claim 1 wherein the HLA Class I mismatches and the at least one HLA Class II mismatch consists of an HLA-A mismatch, a HLA-B mismatch, a HLA-C mismatch, a HLA-G mismatch, a HLA-DR mismatch, a HLA-DQ mismatch and a HLA-DP mismatch. 15. The method of claim 1 wherein the treatment of human cells by the appropriate subset of the set of lentivirus vectors comprises permanently integrating each of the lentivirus vectors of the subset into the human cells.

Details for Patent 9,677,087

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2024-05-18